Curia

Particle Dynamics Announces Anish Parikh as New Chief Commercial Officer

Retrieved on: 
Friday, August 25, 2023
Health, Technology, Manufacturing, Health Technology, Other Technology, Other Manufacturing, Pharmaceutical, Rutgers University, Curia, MBB, Ajinomoto, OSD, Psychology, Catalent, Microsoft Dynamics 365, Marketing, Management, Fine chemical

Particle Dynamics, a leader in oral solid dosage (OSD) technologies for the pharmaceutical sector, has appointed Anish Parikh as its Chief Commercial Officer, effective today.

Key Points: 
  • Particle Dynamics, a leader in oral solid dosage (OSD) technologies for the pharmaceutical sector, has appointed Anish Parikh as its Chief Commercial Officer, effective today.
  • Anish's appointment is a significant step for Particle Dynamics, signaling a commitment to delivering increased value to clients and stakeholders.
  • Nicolas Fortin, Chief Executive Officer of Particle Dynamics, shared, “We're pleased to have Anish lead our commercial team.
  • His background aligns well with our commitment to offering the industry top-notch technologies and excellent service.”
    Anish brings over 25 years of industry experience to Particle Dynamics.

Chain Pharmaceuticals GmbH Announces Its Phytocannabinoid Drug Discovery Platform

Retrieved on: 
Tuesday, November 15, 2022
Curia, Intel Corporation v. CPM United Kingdom Ltd., Union, AI, Pharmacology, Doctor of Philosophy, Machine learning, EMA, Artificial intelligence, Algorithm, Patient, Intel, CIO, Cannabis, GDPR, PAREXEL, Medicine, CHMP, Drug development, Research, Charles University, Cannabinoid, AM, Intelligence, Entrepreneurship, Health, Drug discovery, Acquisition, Pharmaceutical industry, Medical device, MD, Ematheudes neurias

FRANKFURT AM MAIN, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for market authorization.

Key Points: 
  • FRANKFURT AM MAIN, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for market authorization.
  • Clinically proven market authorized medications are sine qua non for long-term demands of all stake-holders throughout European healthcare systems, explains Dr. Pierre Debs, Founder and Chief Executive Officer of Chain Pharmaceuticals GmbH.
  • Chain Pharmaceuticals patient data-gathering app, HealChain, is designed with Innoplexus app and its capabilities of data extraction with AI algorithms.
  • Chain Pharmaceuticals GmbH is a German-based drug discovery company using real world data, machine-learning and artificial intelligence to rapidly design and execute clinical trials leading to market-authorized phytocannabinoid products.

Biologics Outsourcing Global Market Report 2022: Advanced Bioprocessing Capabilities of Bioservice Providers Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 18, 2022
Health, General Health, Samsung Biologics, Prevalence, Cros, LNP, Biotechnology, Degenerative disease, Cognate, Partnership, Infection, CDMO, DNA, CGT, Acquisition, RNA transfection, A-DNA, Curia, Geography, Therapy, RNA, Organization, Vaccine, Fine chemical, Pharmaceutical industry

The biologics outsourcing global market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $106.7 billion by 2030.

Key Points: 
  • The biologics outsourcing global market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $106.7 billion by 2030.
  • Major drivers for the biologics outsourcing market include increasing trend of outsourcing among the biopharma companies for gaining an economical access to advanced biologics development and manufacturing capacities and capabilities, advanced bioprocessing capabilities of bioservice providers, increasing approvals and adoption of biologics, increasing R&D spend of biopharma companies and escalating approvals and uptake of biosimilars.
  • The biologics outsourcing global market has been segmented based on the developmental phase, product, end users and geography.
  • Based on the phase, biologics outsourcing global market segmented into discovery, pre-clinical, clinical and commercial phases of biologics development.

GTCR Announces Several Promotions

Retrieved on: 
Monday, October 31, 2022
Leadership, Social, Wendell Pritchett, Therapy, Curo, BS, Software, MBA, Investment, Certification Commission for Healthcare Information Technology, Raphitoma harpula, Health care, GTCR, Cole-Parmer, Kalamazoo College, Environment, Notre Dame, Principal, Chicago (franchise), Biology, Mathematics, Curia, University, Harvard Business School, Technology, Financial services, BBA, Inteliquent, Information services, CFA, Culture, Consumer service, Dermatology, California Business, Consumer Services and Housing Agency, Economics, KJ, Duke University, Advent International, Partnership, Wharton School of the University of Pennsylvania, Business, BA, Growth, Hospital, Management, Northwestern University, Telecommunication, Landmark Aviation

CHICAGO, Oct. 31, 2022 /PRNewswire/ -- GTCR, a leading private equity firm, announced today the promotion of Luke Marker, Stephen Master and KJ McConnell to Managing Director. These three long-tenured investment professionals have contributed significantly to numerous GTCR investments while helping build the firm's culture and franchise.  Additionally, GTCR announced the promotions of two investment professionals, Christopher Smith and Geoffrey Tresley, to Principal as well as the hiring of Ashwin Krishnan as a Principal.  

Key Points: 
  • These three long-tenured investment professionals have contributed significantly to numerous GTCR investments while helping build the firm's culture and franchise.
  • Additionally, GTCR announced the promotions of two investment professionals, Christopher Smith and Geoffrey Tresley, to Principal as well as the hiring of Ashwin Krishnan as a Principal.
  • Promoted to Managing Director from Principal:
    Mr. Marker joined GTCR in 2009.
  • Since its inception, GTCR has invested more than $24 billion in over 270 companies, and the firm currently manages over $27 billion in equity capital.

Development, Manufacturing, and Characterization of mRNA-based Therapeutics, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, February 8, 2022
Industry, Curia, Food, Technology, Doctor of Philosophy, Research, Therapy, RNA transfection, Chemistry, Vaccine, Biology, Development, COVID-19, XTalk

The power of the technology was demonstrated with the rapid development of COVID-19 vaccines and it has the potential to treat previously intractable diseases.

Key Points: 
  • The power of the technology was demonstrated with the rapid development of COVID-19 vaccines and it has the potential to treat previously intractable diseases.
  • Register for this webinar to learn about:
    Join Curia's Vice President, Global Head of R&D Technology, Norman Garceau, PhD for the live webinar on Wednesday, February 23, 2022 at 2pm EST.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Tryp Therapeutics Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights

Retrieved on: 
Wednesday, December 22, 2021
Solidified, Psilocybin, University of Wisconsin–Madison, CSE, FDA, System, SAB, Curia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chronic pain, IND, Fibromyalgia, Optimism, Psychotherapy, University, Binge eating disorder, Coronavirus Scientific Advisory Board (Turkey), Mission statement, Investigational New Drug, API, Company, Disclosure, SAN, Completeness, Therapy, Research, Food, PFN, University of California, San Diego, Pharmaceutical industry, Fine chemical, Radiant exposure, Operation Web Tryp

SAN DIEGO, Dec. 22, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of its audited financial statements for the fiscal year ending August 31, 2021 and reported on corporate highlights from 2021.

Key Points: 
  • SAN DIEGO, Dec. 22, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of its audited financial statements for the fiscal year ending August 31, 2021 and reported on corporate highlights from 2021.
  • A collaboration with Fluence to support the design and implementation of innovative psychotherapy to be used in combination with Tryp's psilocybin-based drug compounds.
  • Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.
  • Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience.

Berkshire Sterile Manufacturing Announces Tyne Jeffrey as the Vice President of Sales

Retrieved on: 
Thursday, August 5, 2021
Business administration, Chief executive officer, University of Massachusetts Amherst Department of Food Science, Curia, University, CTO, Sterilization, Salve Regina University, BSM, Business, Amri, Syringe, Pall Corporation, GLOBE, Management

The company announced the promotion of Tyne Jeffrey from the Director of Business Development to the Vice President of Sales.

Key Points: 
  • The company announced the promotion of Tyne Jeffrey from the Director of Business Development to the Vice President of Sales.
  • Tyne has over 18 years of experience in business development at several leading pharmaceutical manufacturing companies.
  • The Vice President of Sales is a key role in BSMs success as well as the success and satisfaction of its clients.
  • We are delighted to have her on our team, commented Berkshire Sterile Manufacturing cofounder and CEO, Dr. Shawn Kinney.

Curia Completes Acquisition of Integrity Bio

Retrieved on: 
Wednesday, August 4, 2021
Research, Venture Capital, Professional Services, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Canon law of the Catholic Church, Curia

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has completed the transaction to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.

Key Points: 
  • Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has completed the transaction to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.
  • We are excited to welcome our colleagues at Integrity Bio to Curia, bringing their deep scientific expertise and their dedication to improving patients lives, said Curia Chairman and CEO John Ratliff.
  • Our investment in this acquisition extends our global footprint and demonstrates our commitment to deepening our scientific know-how, particularly in biologics.
  • Integrity Bio will migrate to the Curia brand in the future.

Curia to Acquire US-Based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Retrieved on: 
Wednesday, July 14, 2021
Research, Venture capital, Genetics, Professional services, Biotechnology, Health, Pharmaceutical, Other Science, Science, Life sciences, Biotechnology, Articles, Pharmaceutical industry, Canon law of the Catholic Church, Curia, Biopharmaceutical

Curia recently announced it has also signed a definitive agreement to acquire Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California.

Key Points: 
  • Curia recently announced it has also signed a definitive agreement to acquire Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California.
  • Our combined capabilities will enable us to partner with our customers by seamlessly providing LakePharmas multi-modality innovation and speed along with fill-finish solutions from Curia.
  • Our agreements with LakePharma and Integrity Bio demonstrate our commitment to expanding and deepening our biologics capabilities to help our customers advance from curiosity to cure.
  • We are excited to join Curias global network, including commercial manufacturing capabilities, in delivering end-to-end integrated biologics solutions to our pharma and biotech clients.

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Retrieved on: 
Tuesday, July 13, 2021
Other Manufacturing, Research, Venture capital, Professional services, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Canon law of the Catholic Church, Curia, Fill and finish, Economic sectors, Economic taxonomy, Economy, Curia, Integrity Bio, CURIA, INTEGRITY BIO

Integrity Bios biologic capabilities are complementary with Curias existing business and will enable Curia to expand its ability to meet customers needs.

Key Points: 
  • Integrity Bios biologic capabilities are complementary with Curias existing business and will enable Curia to expand its ability to meet customers needs.
  • Curia has decades of experience in managing complexity from R&D through manufacturing, said Curia Chairman and CEO John Ratliff.
  • As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing.
  • Integrity Bio is a privately owned company focused on providing large molecule formulation and fill/finish services to the biotech and pharmaceutical industries.